Automate Your Wheel Strategy on BIVI
With Tiblio's Option Bot, you can configure your own wheel strategy including BIVI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: February 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Read More
BioVie could offer first new Parkinson's therapy in decades
Published: February 11, 2026 by: Proactive Investors
Sentiment: Positive
In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW), a clinical-stage biopharmaceutical company with a market capitalization still measured in the tens of millions, is attempting exactly that by targeting what it believes is a root driver of neurodegeneration rather than merely treating symptoms.
Read More
BioVie hits enrolment milestone in early Parkinson's trial, data due later this year
Published: January 16, 2026 by: Proactive Investors
Sentiment: Positive
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson's disease, putting the group on track for key data later this year. The Phase 2 study, known as SUNRISE-PD, has enrolled 60 patients who were diagnosed within the past four years and have not yet been treated with standard levodopa therapy.
Read More
What Makes BioVie (BIVI) a New Buy Stock
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
BioVie (BIVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc (Yale University), who will join company management to discuss the unmet need and current treatment landscape for long COVID on Thursday, April 10, 2025 at 10:00 AM ET. To register, click here .
Read More
About BioVie Inc. (BIVI)
- IPO Date 2020-09-18
- Website https://bioviepharma.com
- Industry Biotechnology
- CEO Cuong Viet Do
- Employees 14